MedTrace Logo

Risk Factors for the Recurrent Postoperative Macular Edema Treated With OZURDEX

NCT05372562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-05-12

No results posted yet for this study

Summary

Patients who were diagnosed as postoperative CME and administrated with intravitreal OZURDEX injection were reviewed. Outcome will include best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT). Recurrent CME and corresponding treatments were recorded.

Conditions

  • Macular Edema

Sponsors & Collaborators

  • Peking University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372562 on ClinicalTrials.gov